Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: triethyl citrate; purified talc; hypromellose; sodium stearylfumarate; glyceryl monostearate; microcrystalline cellulose; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); crospovidone; magnesium stearate; povidone; polysorbate 80; macrogol 6000; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: sodium stearylfumarate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; polysorbate 80; glyceryl monostearate; crospovidone; magnesium stearate; purified talc; hyprolose; macrogol 6000; triethyl citrate; hypromellose; microcrystalline cellulose; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: crospovidone; sodium stearylfumarate; microcrystalline cellulose; hypromellose; polysorbate 80; glyceryl monostearate; macrogol 6000; triethyl citrate; purified talc; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; magnesium stearate; hyprolose; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.5 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: purified talc; hypromellose; crospovidone; polysorbate 80; magnesium stearate; glyceryl monostearate; hyprolose; macrogol 6000; sodium stearylfumarate; triethyl citrate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; microcrystalline cellulose; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: crospovidone; magnesium stearate; methacrylic acid - ethyl acrylate copolymer (1:1); macrogol 6000; triethyl citrate; hyprolose; povidone; microcrystalline cellulose; glyceryl monostearate; hypromellose; sodium stearylfumarate; purified talc; polysorbate 80; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); hyprolose; triethyl citrate; crospovidone; glyceryl monostearate; macrogol 6000; povidone; microcrystalline cellulose; purified talc; hypromellose; magnesium stearate; sodium stearylfumarate; polysorbate 80; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); crospovidone; iron oxide red; polysorbate 80; hyprolose; macrogol 6000; glyceryl monostearate; microcrystalline cellulose; povidone; macrogol 400; purified talc; magnesium stearate; hypromellose; sodium stearylfumarate; titanium dioxide; iron oxide yellow; triethyl citrate; maize starch; sucrose - healing of duodenal ulcer associated with helicobacter pylori. ,eradication of helicobacter pylori in patients with active or healed peptic ulcers.

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers. patients are considered to be at risk due to their age (≥ 60) and/or d

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - adults esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed ee in adults. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of ee in pediatric patients 12 years to 17 years of age.  esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of ee in adults. controlled studies do not extend beyond 6 months. adults esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsul

United States - English - NLM (National Library of Medicine)

proficient rx lp - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered.   in infants 1 month to less than 1 year, esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated gerd.   maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months.   symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with ger